5-甲基-1-丙基-3-吡唑羧酸 | 956950-99-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-甲基-1-丙基-3-吡唑羧酸
• 英文名称: 5-methyl-1-propyl-1H-pyrazole-3-carboxylic acid
• 英文别名: 5-methyl-1-propylpyrazole-3-carboxylic acid
• CAS: 956950-99-5
• 化学式: C₈H₁₂N₂O₂
• mdl: MFCD08700640
• 分子量: 168.19
• InChiKey: HLTNVXVETKMVLM-UHFFFAOYSA-N

物化性质

• 沸点：
  319.2±22.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] HETEROCYCLIC AMIDES AS KINASE INHIBITORS<br/>[FR] AMIDES HÉTÉROCYCLIQUES À UTILISER EN TANT QU'INHIBITEURS DE KINASE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2014125444A1

  公开（公告）日：2014-08-21

  Disclosed are compounds having the formula (I) wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.

  揭示了具有式（I）的化合物，其中X、Y、Z1、Z2、Z3、Z4、R5、RA、m、A、L和B如本文所定义，并公开了制备和使用这些化合物的方法。
• HETEROCYCLIC AMIDES AS KINASE INHIBITORS
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US20170183332A1

  公开（公告）日：2017-06-29

  Disclosed are compounds having the formula: wherein X, Y, Z 1 , Z 2 , Z 3 , Z 4 , R 5 , R A , m, A. L, and B are as defined herein, and methods of making and using the same.

  本发明涉及具有以下结构式的化合物：其中X、Y、Z1、Z2、Z3、Z4、R5、RA、m、A、L和B如本文所定义，以及制备和使用它们的方法。
• DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS
  申请人：YAMASHITA Hiroshi

  公开号：US20120028920A1

  公开（公告）日：2012-02-02

  A heterocyclic compound or a salt thereof represented by the formula (1): where R 2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R 1 represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  一种由式（1）所表示的杂环化合物或其盐：其中R2代表氢原子或较低的烷基基团；A代表较低的烷基烯基基团；R1代表芳香基团或杂环基团。本发明的化合物具有广泛的治疗精神障碍的光谱，包括中枢神经系统障碍，无副作用且安全性高。
• Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders
  申请人：Otsuka Pharmaceutical Co., Limited

  公开号：EP2284169A1

  公开（公告）日：2011-02-16

  A heterocyclic compound or a salt thereof represented by the formula (I): where R2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or a lower alkenylene group; and R1 represents a benzene fused heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  一种杂环化合物或其盐，由式（I）代表： 其中 R2 代表氢原子或低级烷基；A 代表低级亚烷基或低级亚烯基；R1 代表苯融合杂环基团。本发明的化合物对包括中枢神经系统疾病在内的精神疾病具有治疗范围广、无副作用、安全性高等特点。
• Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders
  申请人：Otsuka Pharmaceutical Co., Limited

  公开号：EP2287161A1

  公开（公告）日：2011-02-23

  A heterocyclic compound or a salt thereof represented by the formula (I): where R2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or a lower alkenylene group; and R1 represents a heteromonocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  一种杂环化合物或其盐，由式（I）代表： 其中 R2 代表氢原子或低级烷基；A 代表低级亚烷基或低级亚烯基；R1 代表杂环基团。本发明的化合物对包括中枢神经系统疾病在内的精神疾病具有治疗范围广、无副作用、安全性高等特点。